Myocardial Ischemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Myocardial Ischemia – Drugs In Development, 2024 report and make more profitable business decisions.
Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris); neck or jaw pain; shoulder or arm pain; clammy skin; shortness of breath; and nausea and vomiting. Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clots, coronary spasms, and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include smoking, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity, and family history.
The Myocardial Ischemia drugs in development market research report provide comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Myocardial Ischemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Myocardial Ischemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Myocardial Ischemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Myocardial Ischemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Anagenics LtdBioCardia Inc
Chrysalis BioTherapeutics Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Gene Biotherapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Imbria Pharmaceuticals Inc
Inflammx Therapeutics Inc
NervGen Pharma Corp
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
University Hospital Geneva
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Myocardial Ischemia reports